Previous 10 | Next 10 |
2024-04-22 15:42:04 ET More on United States 10-Year Bond Yield: Wall Street Lunch: Bond Bulls In Hibernation Dollar Consolidates But Adjustment Is Not Over Wall Street Lunch: So Long Summer Of Rate Cuts Bond yields tick down as cash moves to safety following...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ). The investigation concerns whether Regeneron and/or certai...
2024-04-16 08:37:08 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...
NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain add...
2024-04-12 12:15:02 ET Truist Financial analyst issues BUY recommendation for REGN on April 12, 2024 10:01AM ET. The previous analyst recommendation was Buy. REGN was trading at $903.175 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
2024-04-12 10:44:43 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now 10 Attractive sell puts within the Russell 1000 - JPM 10 Attractive buy puts within the Russell 1000 - JPM Seeking Alpha’s Quant Rat...
2024-04-11 08:55:34 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...
2024-04-10 17:09:55 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...
TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) a...
2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...